Use of cyclin D1 as a pharmacodynamic (PD) endpoint biomarker of SHetA2 chemoprevention activity was supported by the observation of a SHetA2 dose-dependent decrease of polyp cyclin D1 levels in association with reduction of the number and sizes of polyps in the APCmin/+ model of colorectal cancer [16]. Here, CCND1 is linked to colorectal cancer.